MyMD Pharmaceuticals (NASDAQ:MYMD) stock fell ~8% on Wednesday amid the company announcing dosing update on its phase 2 trial of MYMD-1 as a therapy for delaying aging and extending healthy lifespan.

The global population is getting older. The trend will lead to lower returns, earnings growth, and valuations, JPMorgan strategists say. If the share of people over 65 increases 1%, returns will ...